Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Q1 2026 earnings

Reported May 13, 2026 · Before market open

EPS-$0.48Beat by $0.04
EPS estimate-$0.52

Next report

Aug 10, 2026 (Tomorrow)
EPS estimate-$0.51

Financials

Q1 2026

Income statement

See full
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation & ratios

Valuation

as of 08/07/26
See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

FAQ

When did Oruka Therapeutics, Inc. report Q1 2026 earnings?
Oruka Therapeutics, Inc. (ORKA) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Oruka Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Oruka Therapeutics, Inc. reported eps of $-0.48 for Q1 2026.
Did Oruka Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.52 by $0.04.
How did Oruka Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 20.0% from $-0.40.
Where can I find Oruka Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 10-Q periodic report (0001213900-26-055769) directly on SEC EDGAR. The filing index links above go to sec.gov.